Synergistic Cancer Therapies Enhanced by Nanoparticles: Advancing Nanomedicine Through Multimodal Strategies
Pharmaceutics · 22.05.2025 · 17 (6) · 682
DOI: 10.3390/pharmaceutics17060682 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 22.05.2025. Verfasst von Seyed Mohamad Sadegh Mousavi-Kiasary und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical and Environmental Sciences, Texas A&M University-Corpus Christi, Corpus Christi, TX 78412, USA. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 266 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Texas A&M University–Corpus Christi.
Abstract (Originalsprache)
Cancer remains a formidable global health challenge due to its complex pathophysiology and resistance to conventional treatments. In recent years, the convergence of nanotechnology and oncology has paved the way for innovative therapeutic platforms that address the limitations of traditional modalities. This review examines how nanoparticle (NP)-based strategies enhance the efficacy of chemotherapy, radiotherapy, phototherapy, immunotherapy, and gene therapy by enabling targeted delivery, controlled drug release, and tumor-specific accumulation via the enhanced permeability and retention (EPR) effect. We discuss the design and functionalization of various organic, inorganic, and hybrid NPs, highlighting their roles in improving pharmacokinetics, overcoming multidrug resistance, and modulating the tumor microenvironment. Particular emphasis is placed on dual and multimodal therapies, such as chemo-phototherapy, chemo-immunotherapy, and gene-radiotherapy, that leverage nanoparticle carriers to amplify synergistic effects, minimize systemic toxicity, and improve clinical outcomes. We also explore cutting-edge advances in gene editing and personalized nanomedicine, as well as emerging strategies to address biological barriers and immunosuppressive mechanisms in the tumor niche. Despite the undeniable promise of nanoparticle-based cancer therapies, challenges related to toxicity, scalable manufacturing, regulatory oversight, and long-term biocompatibility must be overcome before they can fully enter clinical practice. By synthesizing recent findings and identifying key opportunities for innovation, this review provides insight into how nanoscale platforms are propelling the next generation of precision oncology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physical and Environmental Sciences, Texas A&M University-Corpus Christi, Corpus Christi, TX 78412, USA.
- School of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA.
- Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
ORCID-Profile: Ashkan Zandi, Nasrin Hooshmand
Förderung
- Texas A&M University–Corpus Christi
Zitieren
APA
Mousavi-Kiasary, S. M. S., Senabreh, A., Zandi, A., Pena, R., Cruz, F., Adibi, A., & Hooshmand, N. (2025). Synergistic Cancer Therapies Enhanced by Nanoparticles: Advancing Nanomedicine Through Multimodal Strategies. Pharmaceutics, 17(6), 682. https://doi.org/10.3390/pharmaceutics17060682
Vancouver
Mousavi-Kiasary SMS, Senabreh A, Zandi A, Pena R, Cruz F, Adibi A, et al. Synergistic Cancer Therapies Enhanced by Nanoparticles: Advancing Nanomedicine Through Multimodal Strategies. Pharmaceutics. 2025;17(6):682. doi:10.3390/pharmaceutics17060682
BibTeX
@article{MousaviKiasary2025,
author = {Mousavi-Kiasary, Seyed Mohamad Sadegh and Senabreh, Ahmood and Zandi, Ashkan and Pena, Rogelio and Cruz, Frances and Adibi, Ali and Hooshmand, Nasrin},
title = {Synergistic Cancer Therapies Enhanced by Nanoparticles: Advancing Nanomedicine Through Multimodal Strategies},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {6},
pages = {682},
doi = {10.3390/pharmaceutics17060682}
}
EUVIMED